BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
Previous close
$390.94
−$8.76 · -2.19%
Regular session · ET · Market data may be delayed.
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
Day range
Current $390.94
52-week range
Current $390.94
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
78
Undervalued
Sentiment
65
Bullish
Risk
30
Moderate Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
Day range
Current $390.94
52-week range
Current $390.94
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.34B USD | 3.81B USD | 2.46B USD | 1.42B USD | 1.18B USD |
| Cost of goods sold | 668.54M USD | 594.09M USD | 379.92M USD | 286.48M USD | 164.91M USD |
| Gross profit | 4.67B USD | 3.22B USD | 2.08B USD | 1.13B USD | 1.01B USD |
| Research and development | 2.15B USD | 1.95B USD | 1.78B USD | 1.64B USD | 1.46B USD |
| Selling, general, and administrative | 2.08B USD | 1.83B USD | 1.51B USD | 1.28B USD | 990.12M USD |
| Operating expenses | 4.23B USD | 3.78B USD | 3.29B USD | 2.92B USD | 2.45B USD |
| Interest income | 70.51M USD | 47.84M USD | 74.01M USD | 52.48M USD | 15.76M USD |
| Interest expense | 58.23M USD | — | — | — | — |
| Depreciation and amortization | 141.69M USD | 171.76M USD | 87.68M USD | 66.28M USD | 46.46M USD |
| Operating income | 447.14M USD | −568.2M USD | −1.21B USD | −1.79B USD | −1.44B USD |
| Net income | 286.93M USD | −644.79M USD | −881.71M USD | −2B USD | −1.46B USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$426.5
9.10% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB254.5M2.43%10.53B USD0.44%$199.54-2.05%
First Trust NYSE Arca Biotechnology Index FundFBT108.97M3.80%2.87B USD0.55%$257-2.20%
Capital Group Global Growth Equity ETFCGGO96.93M0.85%11.4B USD0.47%$34.38-4.34%
Global X China Biotech ETF (HKD)2820.HK65.43M12.33%621.89M HKD0.68%HK$63.56-4.22%
Capital Group Global Equity ETFCGGE26.16M0.82%3.2B USD0.47%$31.25-3.67%
Capital Group New Geography Equity ETFCGNG19.23M0.67%2.86B USD0.64%$29.91-4.13%
Capital Group International Equity ETFCGIE16.48M0.70%2.35B USD0.54%$33.33-3.22%
VanEck Biotech ETFBBH15.4M3.03%502.68M USD0.35%$239.49-1.31%
iShares Biotechnology ETFIBB
First Trust NYSE Arca Biotechnology Index FundFBT
Capital Group Global Growth Equity ETFCGGO
Global X China Biotech ETF (HKD)2820.HK
Capital Group Global Equity ETFCGGE
Capital Group New Geography Equity ETFCGNG
Capital Group International Equity ETFCGIE
VanEck Biotech ETFBBHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.